Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $566 thousand versus the consensus estimate of $370 thousand.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

Earnings

Sanofi and Lexicon Pharmaceuticals To Collaborate on Sotagliflozin, an Investigational New Oral Medicine for People with DiabetesNovember 6, 2015 8:00 AM Sanofi (SNY), Lexicon Pharma (LXRX) Enter Sotagliflozin Commercialization, Development AgreementNovember 6, 2015 6:26 AM Form 8-K LEXICON PHARMACEUTICALS, For: Nov 06November 6, 2015 6:09 AM Form 8-K LEXICON PHARMACEUTICALS, For: Nov 05November 6, 2015 6:07 AM Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For SotagliflozinNovember 6, 2015 6:00 AM